Vanguard Group’s TG Therapeutics TGTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $472M | Buy |
15,841,002
+319,703
| +2% | +$10.4M | 0.01% | 1097 |
|
|
2025
Q3 | $561M | Sell |
15,521,299
-288,018
| -2% | -$9.49M | 0.01% | 1005 |
|
|
2025
Q2 | $569M | Buy |
15,809,317
+204,805
| +1% | +$7.62M | 0.01% | 954 |
|
|
2025
Q1 | $615M | Buy |
15,604,512
+8,032
| +0.1% | +$270K | 0.01% | 876 |
|
|
2024
Q4 | $469M | Buy |
15,596,480
+209,190
| +1% | +$6M | 0.01% | 1071 |
|
|
2024
Q3 | $360M | Buy |
15,387,290
+1,695,600
| +12% | +$37M | 0.01% | 1220 |
|
|
2024
Q2 | $244M | Buy |
13,691,690
+154,858
| +1% | +$2.47M | ﹤0.01% | 1388 |
|
|
2024
Q1 | $206M | Sell |
13,536,832
-134,112
| -1% | -$2.14M | ﹤0.01% | 1501 |
|
|
2023
Q4 | $233M | Buy |
13,670,944
+199,770
| +1% | +$2.32M | 0.01% | 1415 |
|
|
2023
Q3 | $113M | Buy |
13,471,174
+16,074
| +0.1% | +$224K | ﹤0.01% | 1741 |
|
|
2023
Q2 | $334M | Buy |
13,455,100
+75,593
| +0.6% | +$1.95M | 0.01% | 1175 |
|
|
2023
Q1 | $201M | Sell |
13,379,507
-2,123,257
| -14% | -$32.3M | 0.01% | 1454 |
|
|
2022
Q4 | $183M | Buy |
15,502,764
+756,372
| +5% | +$5.49M | 0.01% | 1479 |
|
|
2022
Q3 | $87.3M | Buy |
14,746,392
+1,725,560
| +13% | +$11.3M | ﹤0.01% | 1879 |
|
|
2022
Q2 | $55.3M | Buy |
13,020,832
+889,869
| +7% | +$5.56M | ﹤0.01% | 2148 |
|
|
2022
Q1 | $115M | Buy |
12,130,963
+39,526
| +0.3% | +$457K | ﹤0.01% | 1861 |
|
|
2021
Q4 | $230M | Buy |
12,091,437
+59,061
| +0.5% | +$1.53M | 0.01% | 1512 |
|
|
2021
Q3 | $400M | Buy |
12,032,376
+307,032
| +3% | +$9.5M | 0.01% | 1122 |
|
|
2021
Q2 | $455M | Buy |
11,725,344
+600,968
| +5% | +$23.6M | 0.01% | 1058 |
|
|
2021
Q1 | $536M | Buy |
11,124,376
+153,513
| +1% | +$7.38M | 0.01% | 911 |
|
|
2020
Q4 | $571M | Buy |
10,970,863
+3,482,786
| +47% | +$118M | 0.02% | 811 |
|
|
2020
Q3 | $200M | Buy |
7,488,077
+2,026,607
| +37% | +$46.6M | 0.01% | 1283 |
|
|
2020
Q2 | $106M | Buy |
5,461,470
+1,007,244
| +23% | +$16.2M | ﹤0.01% | 1647 |
|
|
2020
Q1 | $43.8M | Buy |
4,454,226
+211,707
| +5% | +$2.67M | ﹤0.01% | 1928 |
|
|
2019
Q4 | $47.1M | Buy |
4,242,519
+323,027
| +8% | +$2.46M | ﹤0.01% | 2137 |
|
|
2019
Q3 | $22M | Sell |
3,919,492
-121,630
| -3% | -$848K | ﹤0.01% | 2441 |
|
|
2019
Q2 | $35M | Buy |
4,041,122
+665,380
| +20% | +$5.03M | ﹤0.01% | 2280 |
|
|
2019
Q1 | $27.1M | Buy |
3,375,742
+1,396,074
| +71% | +$7.55M | ﹤0.01% | 2367 |
|
|
2018
Q4 | $8.12M | Sell |
1,979,668
-1,078,412
| -35% | -$5.36M | ﹤0.01% | 2868 |
|
|
2018
Q3 | $17.1M | Buy |
3,058,080
+268,483
| +10% | +$3.07M | ﹤0.01% | 2650 |
|
|
2018
Q2 | $36.7M | Buy |
2,789,597
+240,893
| +9% | +$3.31M | ﹤0.01% | 2291 |
|
|
2018
Q1 | $36.2M | Buy |
2,548,704
+122,994
| +5% | +$1.57M | ﹤0.01% | 2234 |
|
|
2017
Q4 | $19.9M | Buy |
2,425,710
+163,203
| +7% | +$1.43M | ﹤0.01% | 2492 |
|
|
2017
Q3 | $26.8M | Buy |
2,262,507
+216,080
| +11% | +$2.46M | ﹤0.01% | 2350 |
|
|
2017
Q2 | $20.6M | Buy |
2,046,427
+255,844
| +14% | +$2.86M | ﹤0.01% | 2445 |
|
|
2017
Q1 | $20.9M | Buy |
1,790,583
+246,404
| +16% | +$1.77M | ﹤0.01% | 2427 |
|
|
2016
Q4 | $7.18M | Buy |
1,544,179
+56,857
| +4% | +$333K | ﹤0.01% | 2891 |
|
|
2016
Q3 | $11.5M | Buy |
1,487,322
+3,189
| +0.2% | +$20.5K | ﹤0.01% | 2624 |
|
|
2016
Q2 | $8.99M | Buy |
1,484,133
+152,700
| +11% | +$1.24M | ﹤0.01% | 2697 |
|
|
2016
Q1 | $11.3M | Buy |
1,331,433
+81,399
| +7% | +$712K | ﹤0.01% | 2546 |
|
|
2015
Q4 | $14.9M | Buy |
1,250,034
+28,011
| +2% | +$354K | ﹤0.01% | 2430 |
|
|
2015
Q3 | $12.3M | Buy |
1,222,023
+124,529
| +11% | +$1.86M | ﹤0.01% | 2493 |
|
|
2015
Q2 | $18.2M | Buy |
1,097,494
+30,502
| +3% | +$483K | ﹤0.01% | 2407 |
|
|
2015
Q1 | $16.5M | Buy |
1,066,992
+20,024
| +2% | +$303K | ﹤0.01% | 2404 |
|
|
2014
Q4 | $16.6M | Buy |
1,046,968
+217,195
| +26% | +$2.83M | ﹤0.01% | 2317 |
|
|
2014
Q3 | $8.85M | Buy |
829,773
+60,743
| +8% | +$563K | ﹤0.01% | 2550 |
|
|
2014
Q2 | $7.22M | Buy |
769,030
+36,048
| +5% | +$230K | ﹤0.01% | 2665 |
|
|
2014
Q1 | $5.06M | Buy |
732,982
+59,821
| +9% | +$354K | ﹤0.01% | 2822 |
|
|
2013
Q4 | $2.63M | Buy |
673,161
+595,225
| +764% | +$2.4M | ﹤0.01% | 3088 |
|
|
2013
Q3 | $397K | Buy |
77,936
+50,321
| +182% | +$308K | ﹤0.01% | 3587 |
|
|
2013
Q2 | $177K | Buy |
+27,615
| New | +$177K | ﹤0.01% | 3653 |
|
Other funds holding TGTX
SCM
CAM
HRCM
Vanguard Group's TGTX Position: Q4 2025 in Review
Vanguard Group increased its TG Therapeutics (TGTX) stake by 2.1% in Q4 2025, buying an estimated $10.4M and bringing the position to 15,841,002 shares worth $472M. The position accounts for 0.01% of the portfolio, ranked #1097.
Vanguard Group first reported a position in TGTX in Q2 2013 and has held it in 51 quarters since. The position peaked at $615M in Q1 2025. 352 funds tracked by Wall St. Rank hold TGTX as of Q4 2025.
- Vanguard Group held 15,841,002 shares of TG Therapeutics worth $472M as of Q4 2025.
- Vanguard Group bought 319,703 TG Therapeutics shares in Q4 2025, an estimated $10.4M.
- TG Therapeutics made up 0.01% of Vanguard Group's portfolio in Q4 2025, its #1097 holding.
- Vanguard Group first reported a position in TG Therapeutics in Q2 2013 and has held it in 51 quarters since.
- Vanguard Group's TG Therapeutics position peaked at $615M in Q1 2025.
- 352 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.